Alumis Inc
Clinical trials sponsored by Alumis Inc, explained in plain language.
-
Psoriasis drug ESK-001 tested for Long-Term safety in new study
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug ESK-001 in people with plaque psoriasis who have already taken part in an earlier ESK-001 study. About 165 adults will receive the treatment and be monitored for side effects and how well their skin clears up.…
Phase: PHASE2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated May 17, 2026 07:00 UTC
-
New lupus drug shows promise in phase 2 trial
Disease control OngoingThis study tests an experimental drug called ESK-001 in adults with lupus (SLE). The goal is to see if it can reduce disease activity better than a placebo over 48 weeks. About 408 participants who have active lupus and are on standard treatments will receive either ESK-001 or a …
Phase: PHASE2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated May 17, 2026 06:52 UTC
-
New hope for psoriasis sufferers: Long-Term drug study underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug ESK-001 for people with moderate to severe plaque psoriasis. About 1,680 adults who have already been in a prior ESK-001 study will take the drug for 24 weeks, then some may switch to a placebo to see how well…
Phase: PHASE3 • Sponsor: Alumis Inc • Aim: Disease control
Last updated May 17, 2026 06:51 UTC